Structure Therapeutics Appoints Ted W. Love, M.D., to Board of Directors
03 août 2023 17h32 HE
|
Structure Therapeutics Inc.
SAN FRANCISCO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for...
Structure Therapeutics Announces Poster Presentations of its Oral GLP-1 Receptor Agonist GSBR-1290 at the American Diabetes Association 83rd Scientific Sessions
07 juin 2023 08h30 HE
|
Structure Therapeutics Inc.
SAN FRANCISCO and SHANGHAI, China, June 07, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small...
Structure Therapeutics to Present at Jefferies Healthcare Conference 硕迪生物应邀出席杰富瑞健康医疗大会并发表专题演讲
31 mai 2023 16h30 HE
|
Structure Therapeutics Inc.
SAN FRANCISCO and SHANGHAI, June 01, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule...
Structure Therapeutics to Present at Jefferies Healthcare Conference
31 mai 2023 16h30 HE
|
Structure Therapeutics Inc.
SAN FRANCISCO and SHANGHAI, May 31, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule...
Structure Therapeutics Initiates Phase 2a Study of Oral GLP-1 agonist GSBR-1290 for the Treatment of Type 2 Diabetes and Obesity
25 mai 2023 16h30 HE
|
Structure Therapeutics Inc.
12-week Phase 2a and Phase 1b multiple ascending dose (MAD) topline results expected to be announced in latter half of fourth quarter 2023 Ethnobridging study initiated in Japanese individuals and...
Structure Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights
18 mai 2023 21h00 HE
|
Structure Therapeutics Inc.
硕迪生物 2023 年第一季度财务报告及近期亮点 Oral GLP-1 agonist GSBR-1290 advancing into Phase 2a study in type 2 diabetes and obesity用于治疗 2 型糖尿病和肥胖症的口服 GLP-1 激动剂 GSBR-1290 项目已推进到临床2a期。 Topline data from Phase...
Structure Therapeutics Announces Poster Presentations at the American Thoracic Society International Conference
18 mai 2023 16h30 HE
|
Structure Therapeutics Inc.
SAN FRANCISCO and SHANGHAI, China, May 18, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule...
Structure Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights
11 mai 2023 16h30 HE
|
Structure Therapeutics Inc.
Oral GLP-1 agonist GSBR-1290 advancing into Phase 2a study in type 2 diabetes and obesity Topline data from Phase 1b multiple ascending dose and Phase 2a studies of GSBR-1290 expected in second half...
硕迪生物2022年第四季度和全年财务业绩以及近期亮点
04 avr. 2023 19h00 HE
|
Structure Therapeutics Inc.
口服GLP-1激动剂GSBR-1290 Phase 1b研究已完成给药预计2023年下半年将获得GSBR-1290 Phase 1b和Phase 2a研究的数据已完成总额为1.853亿美元的扩大规模首次公开募股 旧金山和上海, April 05, 2023 (GLOBE NEWSWIRE) --...
Structure Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights
30 mars 2023 16h30 HE
|
Structure Therapeutics Inc.
Completed dosing of Phase 1b study of oral GLP-1 agonist GSBR-1290Topline data from Phase 1b and Phase 2a studies of GSBR-1290 expected in 2H 2023Completed $185.3 million upsized initial public...